Healthy Clinical Trial
Official title:
Effects of Including 30-s Sprints During Low-intensity Cycling Exercises During a Training Camp on Performance and Muscle/Blood Characterisitcs
To investigate the effects of Including 30-s sprints during low-intensity cycling exercises during a training camp on performance and muscle/blood characterisitcs in elite cyclists
Inclusion of sprint intervals during low-intensity training (LIT) sessions has been suggested as a potential mean to improve endurance performance in elite cyclists, facilitated by muscular or systemic physiological adaptations. So far, the effects of such training has been studied exclusively in context of short-lasting low-intensity sessions, representing a scenario with suboptimal ecological validity for such highly trained athetes. This study will investigate the effects of including sprints during prolonged LIT-sessions sessions during a 14-day training camp focusing on LIT, followed by 10 days recovery (REC), on performance and performance-related measures in elite cyclists. During the training camp, a sprint training group will conduct 12x30-s maximal sprints during five LIT sessions, whereas a control group will perform distance-matched LIT-only. Overall, the training camp will lead to substantial increases in training load compared to habitual training in both intervention groups, followed by subsequent reductions during REC. Performance tests will be conducted before the training camp (T0) and after REC (T2). Muscle biopsies, hematological measures and stress/recovery questionnaires will be collected Pre (T0) and after the camp (T1). The study was pre-registered at Norwegian Center for Research Data (14/08/2017, Norwegian): http://pvo.nsd.no/prosjekt/55322 ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |